Literature DB >> 18678833

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

Leo H Wang, Eugene M Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18678833     DOI： 10.1212/01.wnl.0000324506.93877.5e

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  15 in total

Review 1.  Beyond the signaling effect role of amyloid-ß42 on the processing of APP, and its clinical implications.

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Exp Neurol       Date:  2010-05-05       Impact factor: 5.330

Review 2.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

3.  Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.

Authors:  Shameem Fawdar; Eleanor W Trotter; Yaoyong Li; Natalie L Stephenson; Franziska Hanke; Anna A Marusiak; Zoe C Edwards; Sara Ientile; Bohdan Waszkowycz; Crispin J Miller; John Brognard
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

4.  The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss.

Authors:  Elizabeth M Kline; Laura M Butkovich; Joshua M Bradner; Jianjun Chang; Harris Gelbard; Val Goodfellow; W Michael Caudle; Malú G Tansey
Journal:  Exp Neurol       Date:  2019-05-08       Impact factor: 5.330

Review 5.  Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase.

Authors:  Harris A Gelbard; Stephen Dewhurst; Sanjay B Maggirwar; Michelle Kiebala; Oksana Polesskaya; Howard E Gendelman
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

6.  The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Authors:  Jennifer Y Zhang; Maria Angelica Selim
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

7.  Neuroprotective activities of CEP-1347 in models of neuroAIDS.

Authors:  Dawn Eggert; Prasanta K Dash; Santhi Gorantla; Huanyu Dou; Giovanni Schifitto; Sanjay B Maggirwar; Stephen Dewhurst; Larisa Poluektova; Harris A Gelbard; Howard E Gendelman
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

Review 8.  Targets for neuroprotection in Parkinson's disease.

Authors:  Talene A Yacoubian; David G Standaert
Journal:  Biochim Biophys Acta       Date:  2008-10-01

9.  The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.

Authors:  Daniel F Marker; Marie-Ève Tremblay; Jenna M Puccini; Justin Barbieri; Mary A Gantz Marker; Colin J Loweth; E Chris Muly; Shao-Ming Lu; Val S Goodfellow; Stephen Dewhurst; Harris A Gelbard
Journal:  J Neurosci       Date:  2013-06-12       Impact factor: 6.167

Review 10.  Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.

Authors:  Byoung Dae Lee; Valina L Dawson; Ted M Dawson
Journal:  Trends Pharmacol Sci       Date:  2012-05-09       Impact factor: 14.819
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.